ImmunityBio Inc

Research ImmunityBio Inc (IBRX) on Bullrun: market cap USD 9.19B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIBRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 9.19B
• Financial periodFY2025
• RevenueUSD 113.29M
• Revenue growth668.3%
• Net income-USD 351.50M
• Free cash flow-USD 308.78M
• Gross margin99.3%

Valuation Snapshot

latest market cap is USD 9.19B.

About ImmunityBio Inc

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Frequently asked questions

What is ImmunityBio Inc's market cap?

ImmunityBio Inc's market capitalization is USD 9.19B.

What does ImmunityBio Inc do?

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.